【摘要】 目的探讨肺腺癌脑转移EGFR突变口服TKi的临床效果观察。方法随机选自2011年1月-2014年1月在本院诊治的肺腺癌脑转移EGFR突变患者68例,随机1:1分成两组,34例予EGFR酪氨酸激酶抑制(EGFR-TKi,)作研究组,34例予全脑放疗联合替莫唑胺作对照组,分析患者的临床近期疗效、毒副反应、生存质量以及总生存期情况。结果研究组生活质量提高率47.06%与改善率85.29%比对照组的26.47%与44.12%高P<0.05),且研究组的平均OS为(15.16±3.27)月比对照组(9.27±2.34)月长(P<0.05)。结论对肺腺癌脑转移EGFR突变患者,予EGFR酪氨酸的激酶抑制(EGFR-TKi)口服,疗效理想,且生存期延长。更多还原

【Abstract】 Objective To observe the clinical effect of oral administration of TKi on EGFR mutations in brain metastasis from adenocarcinoma of lung. Methods The data were selected randomly in our hospital for treatment from January2011 to January 2014. The selected 68 cases of patients with EGFR mutation in brain metastases from lung adenocarcinoma were divided equally into two groups in accordance with the completely random method,the study group whose 34 cases were given EGFR tyrosine kinase inhibition( EGFR-TKi,gefitinib),and the control group in which the 34 cases received whole brain radiotherapy combined with temozolomide. The short-term clinical curative effect,toxic and adverse reaction,quality of life and overall survival of these patients were analyzed. Results The proportion of increased quality of life in the study group was 47. 06% and improvement rate was 85. 29%,both higher than those of the control group,which were respectively 26. 47% and 44. 12%,( P < 0. 05),while the average OS of study group,( 15. 16 ± 3. 27)months was longer than that of the control group,( 9. 27 ± 2. 34) months( P < 0. 05). Conclusion EGFR tyrosine kinase inhibition( EGFR-TKi),Gefitinib is of satisfactory effect for treatment of EGFR mutations in brain metastasis from adenocarcinoma of lung.更多还原